






To the Editor: Poliomyelitis 
outbreaks caused by pathogenic 
vaccine-derived polioviruses (VDPVs) 
are primarily a result of low polio 
vaccine coverage. Low coverage 
enables interhuman circulation of 
polioviruses (PVs) from the oral polio 
vaccine (OPV), and it enables genetic 
drift of the viruses and their subsequent 
reversion to neurovirulent phenotypes 
(1). Polio outbreaks associated with 
type 2 or 3 VDPVs (VDPV2s or 
VDPV3s) were reported in 2001–
2002 and 2005 in Toliara Province 
in southern Madagascar (2,3). These 
VDPVs were found in patients with 
acute flaccid paralysis (AFP) and in 
healthy children who were contacts 
of the patients with AFP (2,4). The 
genomes of these VDPVs belong to 
several independent, complex mosaic 
recombinant lineages composed 
of sequences derived from vaccine 
polioviruses and other co-circulating 
species C human enteroviruses (human 
EV-C) (4,5). The 2001–2002 and 2005 
outbreaks in Toliara Province were 
stopped after rapid and efficient OPV 
vaccination campaigns.
No polio cases have been 
detected in Madagascar since 2005. 
However, OPV coverage fluctuates 
in Toliara Province. In June 2011, to 
determine if VDPVs were circulating 
in the province, we collected fecal 
samples from 616 healthy residents 
<5 years of age (Madagascar Ethics 
Committee agreement 011-MSANP/
CE). Sample extracts were used to 
inoculate human RD and HEp-2c 
cells and mouse L cells expressing the 
human poliovirus cellular receptor 
CD155 (L20B cells) (6). Of the 616 
samples, 238 induced cytopathogenic 
effects in human cells, of which 20 
also induced cytopathogenic effects 
in L20B cells; the latter samples were 
confirmed by reverse transcription 
PCR molecular testing (7) to contain 
PV strains. All PV isolates originated 
from children who had not received 
OPV in the 30 days before samples 
were collected. 
We sequenced the genomic 
regions encoding the capsid viral 
protein (VP1) of the 20 isolates 
confirmed to contain PV strains: 3 
type 2 PV isolates showed >0.5% nt 
sequence divergence from the type 2 
OPV strain (Sabin 2) and were thus 
identified as potentially pathogenic 
VDPV2s. Two of these VDPV2s 
carried numerous mutations in the 
VP1 region (903 bp): isolates MAD-
2593-11 (30 nt mutations) and MAD-
2642-11 (33 nt mutations). The third 
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Figure.	Phylogenetic	trees	showing	genetic	relationships	between	sequences	of	vaccine-
derived	 poliovirus	 (VDPV)	 isolates.	 The	 trees	 are	 based	 on	 nucleotide	 sequence	
alignments	of	various	subgenomic	regions.	Multiple	sequence	alignments	were	performed	
with	CLC	Main	Workbench	5.7.2	software	(CLC	bio,	Aarhus,	Denmark).	Phylograms	were	
constructed	 with	 MEGA4	 (http://megasoftware.net/mega4/mega.html),	 using	 the	 Jukes-
Cantor	algorithm	for	genetic	distance	determination	and	the	neighbor-joining	method.	The	
robustness	of	the	resulting	trees	was	assessed	with	1,000	bootstrap	replications.	A)	Tree	




accession	 no.)	 are	VDPV	 isolates	 recovered	 in	Madagascar	 in	 2011,	 2005,	 and	 2001–
2002,	 respectively.	Sequences	of	other	 isolates	(CV-A11,	13,	and	17)	 from	Madagascar	
were	 also	 used.	The	 percentage	 of	 bootstrap	 replicates	 is	 indicated	 at	 nodes	 if	 >70%.	




VDPV2, MAD-2675–11, carried 6 nt 
mutations. The nucleotide differences 
between Sabin 2 and MAD-2593–11 
(3.3%) and MAD-2642–11 (3.6%) 
suggest that these VDPV2s had been 
multiplying or circulating for ≈3.0 
years, and the differences between 
Sabin 2 and MAD-2675–11 suggest it 
had been multiplying or circulating for 
≈0.5 year. Almost complete genomic 
sequencing, from nt 36 to nt 7,420 
(Sabin 2 numbering), was subsequently 
performed (EMBL accession nos. 
HF913426– HF913428). 
Isolate MAD-2675–11 was 
shown to be a mutated Sabin 2 PV, 
but isolates MAD-2593–11 and 
MAD-2642–11 displayed mosaic 
recombinant genomes composed 
of sequences derived from Sabin 
2 and other human EV-Cs. Both 
recombinants had the 5′–untranslated 
region (UTR), the nonstructural P2–
P3 regions, and the 3′-UTR derived 
from non-PV human EV-C. The 2 
recombination sites were similarly 
located in each of these recombinant 
genomes (approximately at nt 760 
and nt 3,368) at the 2 extremities of 
the structural genomic P1 region. 
Although these recombinants appeared 
to be related, they had different non-
PV human EV-C sequences in the 
P2–P3 region and the 3′-UTR (6.0%–
20.0% nt sequence difference). The 
phylogenetic relationship of these 
isolates to the previous Madagascar 
VDPV2s was assessed: the 2011 
isolates originated from 2 novel, 
independent events (Figure). The 2011 
VDPVs had lost the major attenuating 
determinants in the 5′-UTR (guanine 
to adenine at nt 481) and VP1 region 
(isoleucine to threonine at codon 143) 
regions (8). This finding strongly 
suggests that the 2011 VDPVs had 
regained a degree of neurovirulence.
Although there is currently no 
evidence of AFP cases linked to 
these new VDPVs, their detection 
in 3 children and their genetic 
characteristics strongly suggest 
insufficient OPV coverage in Toliara 
Province. We could obtain proof of 
vaccination (vaccination card) for 
only 27% of the participants. To 
prevent a third poliomyelitis outbreak, 
the Ministry of Health of Madagascar 
organized house-to-house OPV 
vaccination campaigns within Toliara 
Province in October and December 
2011 and in January 2012. No polio 
cases have been reported in the 
province since then, suggesting that 
VDPV circulation was limited or 
stopped by these campaigns.
Massive OPV immunization 
campaigns worldwide have greatly de-
creased the frequency of poliomyelitis 
caused by wild-type PVs. However, 
after the disease has been eliminated 
in developing countries, low polio 
vaccine coverage frequently enables 
the emergence of VDPVs or the 
reintroduction of wild-type PV from 
disease-endemic countries; both 
scenarios threaten the success of the 
poliomyelitis eradication program 
(9,10). More than 640 polio cases 
caused by circulating VDPVs have 
been reported in 21 developing 
countries. We have shown that even in 
the absence of polio cases, potentially 
pathogenic circulating VDPVs can be 
detected in fecal samples collected 
from children living in areas with 
fluctuating and often low polio vaccine 
coverage. Thus, such sampling can 
help determine whether vaccine 
campaigns should be implemented 
in areas where polio could reemerge. 
In Madagascar, vaccination appears 
to have cleared emerging VDPVs 
and to have prevented polio cases in 
children.
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Hepatitis E  
Outbreak, Dadaab 
Refugee Camp,  
Kenya, 2012
To the Editor: Hepatitis E vi-
rus (HEV) is transmitted through 
the fecal-oral route and is a common 
cause of viral hepatitis in developing 
countries. HEV outbreaks have been 
documented among forcibly displaced 
persons living in camps in East Africa, 
but for >10 years, no cases were docu-
mented among Somali refugees (1,2). 
On August 15, 2012, the US Centers 
for Disease Control and Prevention 
(CDC) in Nairobi, Kenya, was noti-
fied of a cluster of acute jaundice syn-
drome (AJS) cases in refugee camps 
in Dadaab, Kenya. On September 5, 
a CDC epidemiologist assisted the 
United Nations High Commissioner 
for Refugees (UNHCR) and its part-
ners in assessing AJS case-patients in 
the camp, enhancing surveillance, and 
improving medical management of 
case-patients. We present the epidemi-
ologic and laboratory findings for the 
AJS cases (defined as acute onset of 
scleral icterus not due to another un-
derlying condition) identified during 
this outbreak. 
Dadaab refugee camp is located in 
eastern Kenya near the border with So-
malia. It has existed since 1991 and is 
the largest refugee camp in the world. 
Dadaab is composed of 5 smaller 
camps: Dagahaley, Hagadera, Ifo, 
Ifo II, and Kambioos. As of Decem-
ber 2012, a total of 460,000 refugees, 
mainly Somalians, were living in the 
camps; >25% were recent arrivals dis-
placed by the mid-2011 famine in the 
Horn of Africa (3). Overcrowding and 
poor sanitation have led to outbreaks 
of enteric diseases, including cholera 
and shigellosis (4); in September 2012, 
an outbreak of cholera occurred simul-
taneously with the AJS outbreak.
During July 2–November 30, 
2012, a total of 339 AJS cases were 
reported from the camps and 2 nearby 
villages: 232 (68.4%) from Ifo II, 57 
(16.8%) from Kambioos, 26 (7.7%) 
from Ifo, 12 (3.5%) from Dagahaley, 
10 (3.0%) from Hagadera, and 1 each 
(0.6%) from the nearby Kenyan vil-
lages of Biyamadow and Darkanley. 
The epidemic curve of the outbreak is 
shown in the Figure.
Of the 339 AJS case-patients, 
184 (54.3%) were female. The over-
all median age was 23.5 years (range 
1 month−91 years). The median age 
among female and male residents was 
24 years and 20 years, respectively. 
Among the 134 women of reproduc-
tive age (15−49 years), 72 (53.7%) 
reported being pregnant; the median 
gestational age was 17.4 weeks (range 
8.7-35.3 weeks). Death was reported 
for 10 of the 339 case-patients (case-
fatality ratio 2.9%), 9 of whom were 
postpartum mothers (case-fatality ra-
tio 12.5%) and 1 a 2-year-old child. 
Serum samples were obtained 
from 170 (50.1%) AJS case-patients 
for testing at the Kenya Medical Re-
search Institute/CDC laboratories in 
Nairobi, Kenya. Of the 170 samples, 
148 were tested for hepatitis E vi-
rus (HEV) IgM by using an ELISA 
Figure.	Cases	of	acute	 jaundice	syndrome,	Dadaab,	Kenya,	July–November	2012.	The	
arrow	 indicates	 the	point	at	which	outbreak	control	measures	 (e.g.,	construction	of	new	
latrines	and	hygiene	messaging)	were	initiated	by	health	authorities.	
